WOBURN, Mass. – CutisPharma announced Wednesday its acquisition of Silvergate Pharmaceuticals and the unveiling of its new corporate brand for the unified company: Azurity Pharmaceuticals. “I am thrilled to announce the combination of two strong companies with a rich legacy meeting the needs of underserved patients, such as children and the elderly,” said Neal Muni,
WILMINGTON, Mass. — CutisPharma reported that the U.S. Food and Drug Administration has approved Firvanq (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. “We are pleased to announce the FDA approval of Firvanq,” Neal Muni, chief executive officer of CutisPharma said
WILMINGTON, Mass. — CutisPharma plans to award an unrestricted grant to the C Diff Foundation to further support its efforts to raise awareness of Clostridium difficile infection (C. difficile). A serious gastrointestinal infection, C. difficile — also known as C diff. — typically affects people who are on antibiotic therapy and/or have experienced a long-term hospitalization or
WILMINGTON, Mass. — Steven Dinh has joined CutisPharma as executive vice president and chief scientific officer. CutisPharma said Monday that Dinh will play a key role at the company, overseeing its efforts to develop its pipeline of drugs for New Drug Application (NDA) submission to the Food and Drug Administration. “We are pleased to have
WILMINGTON, Mass. — CutisPharma has entered into active pharmaceutical ingredient (API) supply and joint development pacts with Dr. Reddy’s Laboratories Ltd. CutisPharma, which focuses on products for the prescription compounding market, said Tuesday that it aims to advance several programs in its research and development portfolio — including RM-02, RM-03 and RM-06 — toward Food
